Osteoporose nach Herztransplantation

U. Lange

doi:10.1055/s-0037-1618147

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2012; 32(06): 361-366
DOI: 10.1055/s-0037-1618147

Sekundäre Formen der Osteoporose

Schattauer GmbH

Osteoporose nach Herztransplantation

Osteoporosis after cardiac transplantation

Authors

U. Lange

¹Universität Gießen

²Abteilung Rheumatologie, Klinische Immunologie, Physikalische Medizin, Osteologie, Kerckhoff-Klinik, Bad Nauheim

Abstract

Zusammenfassung

Die Transplantation stellt eine etablierte Therapie im Endstadium von Herzerkrankungen dar. Ein Knochenverlust zählt zu den häufigen Komplikationen nach Herztransplantation. Die kritische Phase des Knochenmasseverlustes und für Frakturen ist der frühe Zeitraum nach der Herztransplantation im Rahmen einer hoch dosierten immunsuppressiven Therapie. Die Pathogenese, das Management des Knochenmasseverlustes nach Herztransplantation und Empfehlungen werden in dem vorliegenden Übersichtsartikel präsentiert.

Summary

Transplantation has become an established therapy for end-stage heart disease. However, bone loss and fractures are common complications after cardiac transplantation. The critical time for the occurrence of vertebral fractures is the early post-transplantation period, when patients receive high doses of immune suppressive medications. The pathogenesis, management of bone loss after cardiac transplantation and recommendations are presented in this current overview.

Schlüsselwörter

Herztransplantation - Immunsuppression - Knochenmasseverlust - Osteoporose

Keywords

Heart transplantation - immune suppression - bone loss - osteoporosis

Full Text

References

Literatur
1 Eurotransplant: ET year. 2010
2 Bleumink GS. et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Europ Heart J 2004; 25: 1614-1619.
3 Rieth A, Richter M, Classen K. et al. Herztransplantation – update 2011. Hess Ärzteblatt 2011; 7: 404-412.
4 Shane E, Mancini D, Aaronson K. et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997; 103: 197-207.
5 Julian BA, Benfield M, Quarles LD. Bone loss after organ transplantation. Transplant Rev 1993; 7: 82-86.
6 Eastell R, Dickson ER, Hodgson SF. et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
7 McDonald JA, Dunstan CR, Dilworth P. et al. Bone loss after liver transplantation. Hepatology 1991; 14: 613-619.
8 Henderson NK, Sambrook PN, Kelly PJ. et al. Bone mineral loss and recovery after cardiac transplantation. Lancet 1995; 346: 905.
9 Shane E, Rivas M, McMahon DJ. et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997; 82: 1497-1506.
10 Horber FF, Casez JP, Steiger U. et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9: 1-9.
11 Spira A, Gutierrez C, Chaparro C. et al. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117: 476-481.
12 Lange U, Müller-Ladner U, Pfeilschifter J. Osteoporose. Der Internist 2011; 52: 843-854.
13 Monegal A, Navasa M, Guañabens N. et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or Ciclosporine A. Calcif Tissue Int 2001; 68: 83-86.
14 Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90: 2456-2465.
15 Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003; 14: 617-630.
16 Shane E, Rivas M, Staron RB. et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 1996; 81: 1740-1746.
17 Shane E, Rivas MC, Silverberg SJ. et al. Osteoporosis after cardiac transplantation. Am J Med 1993; 94: 257-264.
18 Nielsen HE, Melsen F, Christensen MS. Spontaneous fractures following renal transplantation: Clinical and biochemical aspects, bone mineral content and bone morphometry. Miner Electrolyte Metab 1979; 2: 323-324.
19 Ramsey-Goldman R, Dunn JE, Dunlop DD. et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14: 456-463.
20 Leidig-Bruckner G, Hosch S, Dodidou P. et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342-347.
21 Rakel A, Sheehy O, Rahme E, Lelorier J. Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study. J Bone Miner Res 2007; 22: 1878-1884.
22 Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003; 9: 321-330.
23 Shane E, Addesso V, Namerow PB. et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350: 767-776.
24 Tauchmanovà L, Colao A, Lombardi G. et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab 2007; 92: 4536-4545.
25 Braith RW, Mills RM, Welsch MA. et al. Resistance exercise training restores bone mineral density in heart transplant recipients. J Am Coll Cardiol 1996; 28: 1471-1477.
26 Braith RW, Conner JA, Fulton MN. et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant 2007; 26: 132-137.
27 Bianda T, Linka A, Junga G. et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2000; 67: 116-121.
28 Sambrook P, Henderson NK, Keogh A. et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15: 1818-1824.
29 Kananen K, Volin L, Laitinen K. et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005; 90: 3877-3885.
30 Atamaz F, Hepguler S, Akyildiz M. et al. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006; 17: 942-949.
31 Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR. et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009; 24: 1335-1344.
32 Monegal A, Guañabens N, Suárez MJ. et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009; 22: 198-206.
33 Bodingbauer M, Wekerle T, Pakrah B. et al. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 2007; 7: 1763-1769.
34 Kaemmerer D, Lehmann G, Wolf G. et al. Treatment of osteoporosis after liver transplantation with ibandronate. Transpl Int 2010; 23: 753-759.
35 Stein EM, Ortiz D, Jin Z. et al. Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab 2011; 96: 3457-3465.
36 Fleischer J, McMahon DJ, Hembree W. et al. Serum testosterone levels after cardiac transplantation. Transplantation 2008; 85: 834-839.
37 Tauchmanovà L, Selleri C, De Rosa G. et al. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med 2005; 118: 664-670.
38 Tauchmanovà L, Selleri C, De Rosa G. et al. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod 2003; 18: 1410-1416.
39 Trombetti A, Gerbase MW, Spiliopoulos A. et al. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 2000; 19: 736-743.
40 Stempfle HU, Werner C, Echtler S. et al. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 1999; 68: 523-530.
41 Isoniemi H, Appelberg J, Nilsson CG. et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 2001; 34: 299-305.
42 Välimäki MJ, Kinnunen K, Tähtelä R. et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int 1999; 10: 128-136.
43 Välimäki MJ, Kinnunen K, Volin L. et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23: 355-361.
44 Cohen A, Addesso V, McMahon DJ. et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 2006; 81: 686-691.